Results 31 to 40 of about 5,351 (123)

Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against <i>Acinetobacter baumannii-calcoaceticus</i> complex strains isolated from respiratory and bloodstream sources: results from ACNBio study. [PDF]

Antimicrob Agents Chemother
Infections caused by carbapenem-resistant complex (ABC) are associated with high mortality rates and limited treatment options. This study aims to evaluate the activity of clinically utilized antimicrobials against a contemporary collection of ABC ...
Buyukyanbolu E, Argotsinger J, Beck ET, Chamberland RR, Clark AE, Daniels AR, Liesman R, Fisher M, Gialanella P, Hand J, Harrington AT, Humphries RM, Huse H, Hamilton-Seth R, Hankins JD, Kufel WD, Riddell SW, Marino J, Westblade LF, Mochon AB, Narayanan N, Kirn TJ, Pierce VM, Potula R, Tekle T, Simner PJ, Tibbetts RJ, Vu C, Abbo LM, Martinez O, Dumm RE, Nicolau DP, Asempa TE, Acinetobacter baumannii Complex National Biorepository (ACNBio) Study Group.   +33 more
europepmc   +2 more sources

In vitro activity of cefiderocol and sulbactam-durlobactam against clinical-isolated carbapenem-resistant Acinetobacter baumannii from China

International Journal of Infectious Diseases
Objectives: This study aimed to evaluate the in vitro activity of cefiderocol and sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates from China and elucidate potential resistance mechanisms.
Yixin Zhang, Mohan Ju, Yumiao Guo, Jinhong Chen, Pei Li, Ying Li   +5 more
doaj   +1 more source

Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory

Antibiotics, 2023
The rapid emergence of multi-drug resistant Gram-negative pathogens has driven the introduction of novel β-lactam combination agents (BLCs) to the antibiotic market: ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem ...
Carmella Russo, Romney Humphries
doaj   +1 more source

Boronic Acid Inhibitors of β‐Lactamases: A Promising Strategy Against Antimicrobial Resistance

Medicinal Research Reviews, EarlyView.
ABSTRACT The rise of antimicrobial resistance (AMR) poses a critical threat to global health, mostly due to the proliferation of β‐lactamases, a class of enzymes responsible for the inactivation of β‐lactam antibiotics. Among the most promising strategies to restore β‐lactam efficacy is the use of β‐lactamase inhibitors (BLIs), with boronic acid ...
Nicolò Santi, Federico Corsini, Robert A. Bonomo, Emilia Caselli, Fabio Prati   +4 more
wiley   +1 more source

Failure of durlobactam to restore the susceptibility to meropenem in carbapenem-resistant Klebsiella pneumoniae

Journal of Global Antimicrobial Resistance
Objective: Durlobactam, a diazabicyclooctane β-lactamase inhibitor, can protect meropenem from hydrolysis of KPC and OXA-48 carbapenemases. This study aims to characterise the genome of a carbapenem-resistant Klebsiella pneumoniae clinical strain with a ...
Hongxia Wen, Yu Feng, Zhiyong Zong
doaj   +1 more source

Comparative Neurotoxicity of Polymyxin B and Colistin in Patients With Cancer

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 10, October 2026.
ABSTRACT Background The polymyxins, polymyxin B and colistin, are last‐line options for the treatment of infections caused by drug‐resistant gram‐negative organisms. The comparative neurotoxicity of these agents using contemporary dosing is poorly understood.
Samuel L. Aitken, Emily R. Aboujaoude, Jovan Borjan, Frank P. Tverdek   +3 more
wiley   +1 more source

Zwitterionic Penicillin‐Derived Sulfone Inhibitor for Combating β‐Lactamase‐Mediated Antibiotic Resistance

ChemMedChem, Volume 21, Issue 9, 14 May 2026.
Combining enhanced permeability strategies with (2‐pyridyl)methylene substitution in the sulbactam scaffold led to a novel β‐lactamase inhibitor to combat β‐lactamase‐mediated resistance to β‐lactam antibiotics. The studies presented highlight the potential of compound 3 as a next‐generation β‐lactamase inhibitor for combating infections caused by ...
Diana Rodríguez, Emilio Lence, Juan C. Vázquez‐Ucha, Alejandro Beceiro, Concepción González‐Bello   +4 more
wiley   +1 more source

Microbial Etiology and Antimicrobial Resistance in Pneumonia Among Hospitalized Patients in Kazakhstan: A Systematic Review and Single‐Arm Meta‐Analysis of Prevalence Data

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov, Maxim Solomadin, Alyona Lavrinenko, Vyacheslav Beloussov, Vitaliy Strochkov, Shynggys Orkara, Nurlan Sandybayev, Sergey Yegorov   +7 more
wiley   +1 more source

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects

, 2019
Sulbactam-durlobactam is being developed for the treatment of infections caused by , including those caused by multidrug- and carbapenem-resistant isolates.
Mamikonyan, Grigor, Preston, Richard A, Isaacs, Robin, Stone, Emily, O'Donnell, John   +4 more
core   +1 more source

A Review of β‐Lactamase Inhibitors in Clinical Use and Development: Mechanisms, Spectrum, and Therapeutic Applications

International Journal of Microbiology, Volume 2026, Issue 1, 2026.
β‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β‐lactamase enzymes.
Mohammad Javad Roustaye Gourabi, Anita Nikoo, Bita Khanbabaei, Masoud Kargar, Amirhossein Fayyazi, Seyyed Mohammad Javad Mousavi, Amirhossein Aghdaee, Ali Hashemi, Javad Yasbolaghi Sharahi, Swaran J. S. Flora   +9 more
wiley   +1 more source